Three airports — in Tampa, Fla.; Des Moines, Iowa and Charleston, S.C. — will be the first in the country to opt in to TSA ...

While immune checkpoint inhibitors and other immunotherapies have revolutionised oncology, therapeutic responses remain highly variable. Most of these ...

Wistar Institute scientists have developed a new type of bispecific T cell engager, or BTE, that is effective against ovarian ...

Novocure Ltd (NASDAQ:NVCR) soared to a new 52-week high on Thursday as investors positioned their portfolios amid a higher ...

Immune checkpoint blockade (ICB) therapy has transformed cancer treatment, but many tumors remain resistant. A new study from ...

Immune checkpoint blockade (ICB) therapy has transformed cancer treatment, but many tumors remain resistant. A new study from ...

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that ...

Amid the rapid evolution of the global biopharmaceutical industry, a growing number of biopharmaceutical players are bri ...

BostonGene, the developer of the leading AI model for tumor and immune biology, today announced a strategic research partnership with Kyoto University, a research institution known for its ...

Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, and ...

Immunosuppression confers markedly elevated cSCC risk, with transplant recipients experiencing 65- to 100-fold higher ...

Prostate tumors can vanish from the immune system’s radar. Now, scientists have found a way to strip away that disguise by changing the length of a single RNA molecule.